Risk factors
Unicycive Therapeutics (UNCY) risk factors
Item 1A of every Unicycive Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks1 dropped8 reworded
The filing reflects ongoing capital raising needs, Nasdaq listing maintenance, and internal controls improvements. A key manufacturing vendor issue caused an FDA Complete Response Letter and a 12-month NDA delay. Insider ownership concentration decreased from 63% to 39%.
Filed Mar 30, 2026 - FY2024 10-K risk factors56 risks
This company has no prior year risk filing and operates as an early-stage biopharmaceutical enterprise with 19 employees. Major risks center on raising capital, obtaining FDA approvals, and relying entirely on third-party manufacturers.
Filed Mar 31, 2025